MX359366B - Composición farmacéutica de liberación sostenida que comprene un agente antibacterial. - Google Patents

Composición farmacéutica de liberación sostenida que comprene un agente antibacterial.

Info

Publication number
MX359366B
MX359366B MX2013004711A MX2013004711A MX359366B MX 359366 B MX359366 B MX 359366B MX 2013004711 A MX2013004711 A MX 2013004711A MX 2013004711 A MX2013004711 A MX 2013004711A MX 359366 B MX359366 B MX 359366B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
carriers
useful
emulsifier
further embodiments
Prior art date
Application number
MX2013004711A
Other languages
English (en)
Other versions
MX2013004711A (es
Inventor
Eric S Burak
Danping Li
David S Dresback
Original Assignee
Melinta Subsidiary Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Subsidiary Corp filed Critical Melinta Subsidiary Corp
Publication of MX2013004711A publication Critical patent/MX2013004711A/es
Publication of MX359366B publication Critical patent/MX359366B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con sistemas de vehículos útiles para composiciones farmacéuticas. Estos vehículos comprendes un emulsionante, y también, en otras modalidades, un adyuvante de disolución polimérica. Estos vehículos son útiles para administrar activos farmacéuticos tales como agentes microbianos.
MX2013004711A 2010-11-01 2011-11-01 Composición farmacéutica de liberación sostenida que comprene un agente antibacterial. MX359366B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40883010P 2010-11-01 2010-11-01
PCT/US2011/058743 WO2012061360A2 (en) 2010-11-01 2011-11-01 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2013004711A MX2013004711A (es) 2013-08-29
MX359366B true MX359366B (es) 2018-09-26

Family

ID=46025057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004711A MX359366B (es) 2010-11-01 2011-11-01 Composición farmacéutica de liberación sostenida que comprene un agente antibacterial.

Country Status (19)

Country Link
US (1) US9409896B2 (es)
EP (1) EP2635307B1 (es)
JP (1) JP5902188B2 (es)
KR (1) KR20140022773A (es)
CN (1) CN103379917B (es)
AU (1) AU2011323594C1 (es)
BR (1) BR112013010714A2 (es)
CA (1) CA2816077C (es)
EA (1) EA028054B1 (es)
ES (1) ES2824898T3 (es)
HU (1) HUE051133T2 (es)
IL (1) IL225952A0 (es)
MX (1) MX359366B (es)
NZ (1) NZ609964A (es)
PT (1) PT2635307T (es)
SG (2) SG190117A1 (es)
UA (1) UA114469C2 (es)
WO (1) WO2012061360A2 (es)
ZA (1) ZA201303177B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010321531C1 (en) 2009-11-23 2020-10-01 Cubist Pharmaceuticals Llc Lipopeptide compositions and related methods
WO2012071324A2 (en) * 2010-11-24 2012-05-31 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
RU2693084C2 (ru) 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
WO2021133279A1 (en) * 2019-12-26 2021-07-01 Santa Farma İlaç Sanayi̇ A.Ş. A solid oral pharmaceutical gemifloxacin mesylate composition with improved release pattern and disintegration mechanism

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719109B2 (en) 1996-05-24 2000-05-04 Merck Sharp & Dohme Corp. Antifungal composition with enhanced bioavailability
CN1207895A (zh) 1997-08-12 1999-02-17 陕西省西安制药厂 一种克拉霉素胶囊
DK0996429T3 (da) 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
GB2331458B (en) 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
KR19990080453A (ko) * 1998-04-17 1999-11-05 성재갑 비가역성 hiv 프로테아제 억제제를 함유하는 약제학적 조성물
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
BR0210867A (pt) * 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
JP5043428B2 (ja) 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
US20060270680A1 (en) 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
US8399660B2 (en) * 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
US20070207222A1 (en) * 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
PE20080117A1 (es) * 2006-03-06 2008-02-22 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
WO2007110878A1 (en) * 2006-03-27 2007-10-04 Panacea Biotec Ltd Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
WO2010046933A2 (en) * 2008-10-22 2010-04-29 Rubicon Research Private Limited Pharmaceutical compositions of taste-masked linezolid

Also Published As

Publication number Publication date
BR112013010714A2 (pt) 2024-01-16
SG10201508982TA (en) 2015-12-30
ZA201303177B (en) 2018-12-19
AU2011323594B2 (en) 2016-12-22
CA2816077C (en) 2021-08-10
EA201390646A1 (ru) 2014-01-30
EA028054B1 (ru) 2017-10-31
JP5902188B2 (ja) 2016-04-13
WO2012061360A2 (en) 2012-05-10
PT2635307T (pt) 2020-11-03
SG190117A1 (en) 2013-06-28
JP2013542226A (ja) 2013-11-21
EP2635307B1 (en) 2020-07-29
ES2824898T3 (es) 2021-05-13
AU2011323594A1 (en) 2013-05-23
EP2635307A2 (en) 2013-09-11
EP2635307A4 (en) 2014-11-05
US20140094463A1 (en) 2014-04-03
AU2011323594C1 (en) 2017-06-01
MX2013004711A (es) 2013-08-29
WO2012061360A3 (en) 2012-07-12
KR20140022773A (ko) 2014-02-25
HUE051133T2 (hu) 2021-03-01
IL225952A0 (en) 2013-07-31
CN103379917B (zh) 2016-10-12
CN103379917A (zh) 2013-10-30
US9409896B2 (en) 2016-08-09
UA114469C2 (uk) 2017-06-26
NZ609964A (en) 2015-08-28
CA2816077A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
IL279304A (en) History of cytotoxic benzodiazepines, preparations containing them and their uses
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2013003137A (es) Nanocapsulas que contienen microemulsiones.
MY169141A (en) Biodegradable compositions, methods and uses thereof
WO2013173789A3 (en) Antisense oligonucleotide compositions
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
PL2132294T3 (pl) Układ nośników substancji czynnych
EP2591792A4 (en) NUCLEIC ACID ADMINISTRATION COMPOSITION, EXCIPIENT COMPOSITION, PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACID ADMINISTRATION COMPOSITION OR EXCIPIENT COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD
PH12015501096A1 (en) Composition for immediate and extended release
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MX2012013855A (es) Compuestos de oligobenzamida y su uso.
EP2548022A4 (en) MULTI-PHASE MICROARRAYS AND USES THEREOF
IN2012DN02793A (es)
UA114469C2 (uk) Фармацевтична композиція, що містить протимікробний агент
MY165088A (en) Pharmaceutical compositions comprising alisporivir
GB2513503A (en) Long-lasting fragrance delivery system
EP2569327A4 (en) EIF4E BINDING PEPTIDES
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2011042077A8 (de) Transdermale therapeutische systeme enthaltend 4-n-butylresorcin

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.*

FG Grant or registration
PD Change of proprietorship

Owner name: MELINTA SUBSIDIARY CORP.